The Division for Medicinal Chemistry (DMC) of the Swiss Chemical Society (SCS)

Emilio Kyburz, Rudolf Giger, Wolfgang Fröstl and Hans Peter Märki

The Division for Medicinal Chemistry (DMC) of the SCS intends to provide a forum for scientists interested in medicinal chemistry and related fields. The DMC organizes or supports symposia, seminars, presentations and courses in order to give medicinal chemists and other scientists opportunities to meet, exchange ideas, discuss specific problems and to get to know each other. The activities of the DMC are co-ordinated with the SCS and the European Federation for Medicinal Chemistry (EFMC) and their meetings. The DMC represents its members within the EFMC, which is represented in the IUPAC Section "Chemistry and Human Health". At present the DMC membership stands at 630 members.

History

Considering the importance of the Swiss Pharmaceutical Industry the DMC was established relatively late, e.g. in comparison to the Medicinal Chemistry Division of the American Chemical Society, which was founded in 1946. The DMC was started by an initiative of chemists of the pharmaceutical industry (A. Kaiser, J. Kalvoda, F. Kunz, E. Kyburz, M. Montavon and U. Renner), who met in January 1984 at Hoffmann-La Roche and discussed the foundation of a Medicinal Chemistry Section within the former Swiss Chemical Society (SCS). This initiative was endorsed by K. Heusler, a former president of the SCS. As a first step the SCS Executive Committee (SCS-EC) nominated a working group composed of F. Kunz (chairman), E. Kyburz (secretary), J. Kalvoda and A. Vasella. In April 1986 a "Declaration of Intent" was drawn up and in autumn of 1987 modification of the regulations of the SCS finally paved the way for official establishment of the DMC. As first task a joint meeting with the GDCh in Freiburg im Breisgau was organized in October 1987. In the same year the DMC obtained the membership of the European Federation for Medicinal Chemistry (EFMC) and was invited to organize the "XIIth International Symposium on Medicinal Chemistry" 1992 in Basel. In 1988 a committee consisting of E. Kyburz (chairman), J. Kalvoda (treasurer), R. Giger (secretary), J.-L. Fauchère, D. Hauser, B. Testa and W.-D. Woggon started to enrol members for the DMC. At the Autumn Meeting of the SCS 1988 the first session on Medicinal Chemistry was organised by the DMC. Plenary lectures were presented by J.-L. Fauchère "Design and Synthesis of Peptide Mimetics" and R. H. Abeles "Inhibition of Serine-Proteases and Esterases by Fluoroketones". The attendance at these meetings and the rapidly rising membership of the DMC clearly confirmed the expectations of the promoters. At the SCS Autumn Meeting 1989 lectures were given by C. R. Ganellin "Designing Drugs for Histamine Receptors" and B. Testa "Mechanism of Chiral Recognition in Pharmacokinetic and Pharmacodynamic Processes". Provisional regulations were prepared for the DMC. The official foundation took place on May 16, 1990 on the occasion of the First Annual Meeting of the DMC. The attendance of more than 1200 scientists at the XIIth International Symposium on Medicinal Chemistry in September 1992 in Basel can be considered as a well deserved success.

Chronicle of the DMC Activities

1st Annual Meeting, May 16, 1990: at Hoffmann-La Roche, Basel, Panel discussion: "Medicinal Chemistry in the Present and in the Future". Moderator was A. Pletscher (Swiss Academy of Medical Sciences, former Head of Research at Hoffmann-La Roche), and the panel members were: A. Eschenmoser (Laboratory for Organic Chemistry of the ETH and former chairman of the SCS), Bernard Testa (Head of the Institute of Medicinal Chemistry, School of Pharmacy, Lausanne and member of the Executive Committee of the DMC), Stephan Guttmann (Head of Research and Development at Sandoz Pharma), Dieter Hinzen (Head of Pharma Research at Hoffmann-La Roche, Basel), Jakob Nüesch (Head of Pharma Research of Ciba-Geigy, Basel) and E. Kyburz (Chairman of the DMC). The lively discussion shed light on topics such as the importance and significance of medicinal chemistry in pharmaceutical research and its relationship to modern biology and gene technology. Whilst some participants believed that a crisis faced chemists involved in drug research, because the role of chemistry was being obscured by the great advances being made in the biological sciences, the majority found this could be more an opportunity than a crisis. These advances make it all the more evident, that the chemist involved in drug research, who by training is an organic chemist, cannot simply remain a specialist who knows "how" to synthesise molecules, but should also be able to decide "what" to synthesise, i.e. he must learn to be a true medicinal chemist. Medicinal chemists and biologists should be equal partners, engaged in a constant dialogue and working together in a multidisciplinary environment to provide creative, innovative solutions to human health problems.

Debate focused on the question of how far a rational approach to drug design can replace the previous, widely employed, empirical approach. It was emphasised that also in the past rational techniques, according to the experience and knowledge of the time, have been applied in drug research (e.g. isosteric replacement, structure activity relationships, etc.). However, in spite of the great advances in the biological sciences, it remains impossible to grasp the full complexity of nature. Therefore, it was concluded, that in the search for new drugs, empirical approaches will remain valid, a prediction that has been corroborated by the recent use of high-through-put screening techniques for a large range of biomolecular targets, using radioligand binding or enzymatic assays in addition to the classical screens against micro-organisms.

The panel concluded that the training of future medicinal chemists should start with a sound basis in organic chemistry. However, the need for those involved in drug research to acquire further knowledge in medicinal chemistry and related disciplines, as well as the development of personal skills was clearly identified. A successful drug researcher needs to be not only a first-rate synthetic organic chemist, with a good understanding of biochemistry, pharmacology, physiology, molecular biology, enzymology, quantitative structure-activity relationships, computational modelling, pharmacokinetics, drug metabolism, toxicology etc. but should also be able to communicate and work effectively within teams, and be ready to learn and keep up with a rapidly expanding field of knowledge. Since it is nearly impossible to find all these qualities in a single individual, chemists involved in drug discovery in the large research teams of the pharmaceutical industry, usually specialise in particular areas. Some scientists are interested primarily in medicinal chemistry and develop knowledge and intuition in this discipline, whilst others cultivate their synthetic skills, a differentiation that is also valid in the different stages of drug discovery and drug development.

The question of how to teach Medicinal Chemistry was addressed by A. Eschenmoser, who sketched a very broad definition of chemistry, which in his view encompasses all biologically relevant molecules, small and large. Therefore, when structure, recognition and kinetics are involved, chemistry is part of biological chemistry and molecular

biology. Therefore, in his opinion it should be sufficient to teach organic chemistry in a broad sense. Nevertheless he advocated finally the establishment of Chairs on Medicinal Chemistry at Organic Chemistry Departments which would be involved in both research and teaching activities. The audience felt, that indeed an opportunity for chemists to learn in time the essentials of medicinal chemistry and to develop the ability to communicate effectively with future team colleagues from other disciplines would be a step in the right direction.

At the end of the round table discussion H.-P. Schreiber, theologist and philosopher highlighted the manifold and complex ethical questions connected with man's scientific, technical and economic activities, in the frame of a pluralistic culture. In our society there is no authority entitled and able to give an ultimate answer to these questions. The widespread consensus of the past century towards the scientific and technical progress, then considered synonymous of social progress, has left place to a diffuse uncertainty, scepticism and even fear. Although often unjustified the latter has to be taken seriously by the scientific and technical communities.

Obviously mankind has problems in developing and using some new scientific and technical discoveries. These problems should be solved in a patient, democratic discussion and brought into a common politics which, while observing man's dignity, should safeguard the freedom of research.

2nd Annual Meeting, May 22, 1991: Auditorium Sandoz. P. Krogsgaard-Larsen: "Drug design strategies in Alzheimer disease. Focus on glutamic acid, GABA and acetylcholine" and H. Timmerman: "Searching for selective ligands of histamine receptors".

3rd Annual Meeting, April 27, 1992: Auditorium Royal, Ciba-Geigy. A. Kessler (Hoffmann-La Roche): "Problems relating to the Basel region as a location for industry and future prospects".

4th Annual Meeting, May 5, 1993: Auditorium Sandoz. Sydney Brenner: "New Genetic Approaches to Human Biology and Medicine" and Hans Lehrach: "Molecular Genetic Analysis of Mammalian Chromosomes".

5th Annual Meeting, May 26, 1994: Org. Chem. Institute of the University of Basel. J.A. Ellman: "Combinatorial Synthesis and Evaluation of Compound Libraries Based upon Pharmacophore Structures".

6th Annual Meeting, May 11, 1995: Org. Chem. Institute of the University of Basel. Peter North, Glaxo, UK: "The Case of Sumatriptan".

7th Annual Meeting, May 9, 1996: Mini-Symposium at the University of Basel (organised together with the Basel Chemical Society and supported by the Pharmaceutical Industries of Basel). "Synthesis of Small Molecules on Solid Phase" with contributions by J. A. Ellman "The Solid-Phase Synthesis of Complex Small Molecules", R. Armstrong "Microchip Encoded Combinatorial Libraries: Generation of a Spatially Encoded Library from a Pool Synthesis", M. J. Kurth "The Solid-Phase Part of Supported Small Molecule Synthesis", and R. Ramage "Consideration of Solid-Phase Synthesis with Reference to Quinolone Antibiotics".

8th Annual Meeting, May 15, 1997: Mini-Symposium at the University of Basel (organised together with the Basel Chemical Society and supported by the Pharmaceutical Industries of Basel). "Application of Combinatorial Libraries to Lead Finding" with contributions by M. Geysen "Combinatorial Chemistry: A New Paradigm for Drug Discovery", E. M. Gordon "Combinatorial Organic Synthesis: Application to Drug Discovery", M. Pavia "Identifying Novel Leads Using Combinatorial Libraries: Issues and Successes", and R. Storer "Solution Phase Combinatorial Chemistry in Lead Generation".

9th Annual Meeting, May 7, 1998: Mini-Symposium at the University of Basel (organised together with the Basel Chemical Society and supported by the Pharmaceutical Industries of Basel). "Bioavailability Aspects in Drug Discovery and Development" with contributions by C. A. Lipinski "The Rule of Five for Oral Drug Absorption", D. Thakker "Orally Absorbed Drugs: Rational Design through Structure-Transport Relationships", O. H. Chan "Multiple-Model Evaluation of Absorption of a Tachykinin Receptor Antagonist", T. Weller "Fibrinogen Receptor Antagonists: From Injectable Drugs to Orally Active Compounds", and R. Albert "SDZ CO 611: A Highly Potent Glycated Analog of Somatostatin with Improved Oral Activity".

10th Annual Meeting 1999: Joint Meeting of the SCS-DMC and the GDCh-Fachgruppe Medizinische Chemie, March 22-23, 1999, Basel see below under Spring Meetings.

11th Annual Meeting, May 4, 2000: Mini-Symposium at the University of Basel (organised together with the Basel Chemical Society and supported by the Pharmaceutical Industries of Basel) on: "Chemical Mechanisms of Toxicity: Basic Knowledge for Designing Safer Chemicals" with contributions by J. Ashby (chairman) "Introductive Remarks", D. M. DeMarini "Mutagenesis: DNA as the Target, DNA Damage, Mutations, Genetic Toxicology", C. Ioannides "Role of Cytochromes P450 in Chemical Toxicity and Carcinogenicity", S. D. Nelson "Structural Moieties found in Chemicals that can form Toxic Metabolites" and Ann Richards "Structure-Activity Relationship Studies and their Role in Predicting and Investigating Chemical Toxicity".

12th Annual Meeting, May 10, 2001: Mini-Symposium at the University of Basel (with support by the Swiss Chemical Society and the companies F. Hoffmann-La Roche AG, Novartis AG and Serono SA, Geneva) on: "Case Histories of Drug Design" with contributions by L. F. Hennequin "Design and structure activity relationship of a new class of vascular endothelian growth factor receptor tyrosine kinase inhibitors", A. Stobie "Glycine N-methyl-D-aspartate antagonists: The discovery of UK's 240,455 and 315,716", P. Hadváry "The case history of Xenical", and P. Bühlmayer "The case history of Diovan".

13th Annual Meeting, May 16, 2002: Short Course at the University of Basel: Prof. F. Diederich: "Principles of Molecular Recognition" with handout of >200 transparencies.

14th Annual Meeting 2003: Second Joint French – Swiss Meeting on Medicinal Chemistry, July 1-4, 2003, Beaune: see below under International Meetings.

15th Annual Meeting, May 13, 2004: Mini-Symposium at the University of Basel on "Research Concepts of Swiss Startup Companies" with contributions by T. Rückle (Serono): "Medicinal Chemistry in the Fast-changing World of Biotechnology", P. Ermert (Polyphor): "Parallel Synthesis of Novel Antiviral Lead Compounds", L. Kellenberger (Basilea Pharmaceutica): "Anti-infective Research at Basilea", A. Raeber (Prionics): BSE Diagnostics: from Surveillance to Food Safety", O. Valdenaire (Axovan): "Axovan: from a Concept to a Success", Sabine Pierau (Morphochem): "Dual Inhibition of NEP (Neutral Endopeptidase) and DPP IV (Dipeptidyl Peptidase IV) as potential Type 2 Diabetes Treatment", and T. Weller (Actelion): "Actelion's Drug Discovery Process: focused Research in Pursuit of Success".

16th Annual Meeting, May 25, 2005: see ILMAC 2005.

17th Annual Meeting, May 18, 2006: Mini-Symposium at the University of Basel "Imaging Technologies for Biomedical Research" with lectures by Matthias Bräutigam (Schering AG, Berlin): "PET-Imaging Agents from Research to Approval (Perspectives from a Pharma Company working on *in vivo* Diagnostics", Pius August Schubiger (ETH Zurich): "Molecular Imaging with PET Tracers and Animal PET Scanner", Markus Rudin (ETH Zurich): "Imaging in Drug Discovery – Structure – Function – Mechanisms", and Hanns Möhler (ETH Zurich): "Brain Function and the Need for Imaging".

18th Annual Meeting, March 18-21, 2007: see ‚Frontiers in Medicinal Chemistry' - Joint German-Swiss Meeting on Medicinal Chemistry (Berlin, Germany).
19th Annual Meeting, May 29, 2008: Mini-Symposium at the University of Basel "Drug Targeting" with lectures by Ruth Duncan (Center for Polymer Therapeutics, Cardiff University): "Polymer Therapeutics and other Nanomedicines as Targetable Cancer Therapies", Iwao Ojima (State University New York, Stony Brook, USA): "Design, Application, and Chemical Biology of Tumor-Targeting Drug Conjugates", Dario Neri (Institute for Pharmaceutical Sciences, ETH Zürich): "Antibody-Based Vascular Tumor Targeting", Nobuo Shimma (Chugai Pharmaceuticals, Kamakura, Japan): "Discovery of Capecitabine (Xeloda), a Rationally Designed and Tumor-Activated Prodrug of 5-Fluorouracil, and Beyond".

Spring Meetings of the SCS organised by DMC
March 31, 1995, Lausanne: "Perspectives in Carbohydrate Research: New Opportunities for Drug Discovery" with contributions by James C. Paulson "Glyco-Information: Sialosides, Sialytransferases and Selectins", Serge Pérez "Carbohydrates-Protein Interactions: The Molecular Aspects", Peter M. Colman "Influenza Virus Neuraminidase Inhibitors - Design and Antiviral Properties" and Beat Ernst "Chemical and Enzymatic Synthesis of Complex Carbohydrates".

March 22-23, 1999, Basel: Second Swiss/German Meeting on Medicinal Chemistry (with the support of the Basel Chemical Society and the Pharmaceutical Industries of Basel): Four Mini-Symposia on:
"Virology" with contributions by J. P. Vacca "The Discovery of Crixivan, an Orally Bioavailable HIV-1 Protease Inhibitor", P. W. Smith "Recent Advances in Sialidase Inhibitors for the Treatment of Influenza", and B. Simoneau "Helicase-Primase Inhibitors as Novel Anti-HIV Agents".
"Multi Drug Resistance" with contributions by W. N. Konings "Multi Drug Resistance from Bacteria to Men: Similarities in Structure and Function", A. R. Safa "Modulation of Multi Drug Resistance in Cancer Cells by Inhibitors of P-Glycoprotein" and A. Garnier-Suillerot "Impaired Accumulation of Drug in Multi Drug Resistant Cells. What are the Respective Contributions of the Kinetics of Uptake and of Transporter-Mediated Efflux of Drug?".
"Immunology" with contributions by M. A. Murcko "The Design of IMPDH Inhibitors", I. Graef "Regulation of Intracellular Signal and Transcription by Induced Proximity Using Synthetic Ligands" and R. Sedrani "Derivatisation of the Immunosuppressive Macrolide Rapamycin: Chemical, Structural and Biological Aspects".
"Gene Therapy" with contributions by R. Mertelsmann "Somatic Cell and Gene Therapy: Perspectives in Oncology", C. Bordignon "Gene Transfer for Immune Therapy of Cancer" and C. J. Leumann "Sugar- and Base-Modified Oligonucleotides for the Sequence-Specific Recognition of Single and Double Stranded RNA and DNA".

Swiss Courses on Medicinal Chemistry, Leysin
These courses are held biennially. They offer young scientists with a few years experience in the pharmaceutical industry and interested Ph.D. students a broad overview of disciplines involved in modern preclinical drug research. The development of integrative abilities is a prerequisite to function in today's multidisciplinary drug discovery teams. The course is set up for synthetic organic chemists, as well as biologists and pharmacologists and those involved in drug design and the

physicochemical characterization of biologically active compounds. Active participation in tutorials and the presentation of case histories are important parts of the course.
1st October 9-14, 1994, organised by H. van de Waterbeemd and B. Testa (17 speakers, 45 participants from industry and 19 students).
2nd October 6-11, 1996, organised by G. Folkers and H. van de Waterbeemd (20 speakers, 40 participants from industry and 22 students).
3rd October 11-16, 1998, organised by B. Testa and G. Folkers (19 speakers, 3 case studies, 3 tutorials, 55 participants from industry and 15 students).
4th October 8-13, 2000, organized by G. Folkers, B. Ernst, H. van de Waterbeemd and B. Testa (17 speakers, 2 case studies, 4 tutorials, 64 participants from industry and 8 students).
5th October 6-11, 2002: organized by G. Folkers and B. Ernst (24 speakers, 3 case studies, 4 tutorials, 77 participants from industry and 11 students).
6th October 10-15, 2004: organized by G. Folkers and B. Ernst (20 speakers, 3 case studies, 3 tutorials, 66 participants from industry and 11 students).
7th October 1-6, 2006: organized by G. Folkers and B. Ernst (22 speakers, 3 case studies, 4 tutorials, maximal number of participants, similar to previous years).
8th October 12-17, 2008: organized by B. Ernst and G. Folkers (30 speakers, 25 lectures, 3 case studies, 8 tutorials, 77 participants from industry, and 18 students).

International Meetings organised by DMC

October 6-10, 1987, Freiburg in Breisgau, Joint Meeting with Fachgruppe Medizinische Chemie GDCh, "New Developments in Medicinal Chemistry: Agonists and Antagonists at Ion-Channels, Receptor Differentiation, Ficts and Facts". 29 lectures and 15 posters. 350 participants.
R. Greger (Univ. Freiburg): “Properties of epithelial Ion Channels”, E. Kyburz (Roche, Basel): “Medicinal Chemistry of Ligands of the Benzodiazepine Receptor”, S. Goldmann (Bayer, Wuppertal) on “New Developments in the Modulation of Calcium Channels”, W. van Drische (Univ. Leuven): “Potassium Channels”, T. Leutert (Ciba-Geigy, Basel): “Chiral Calcium Channel Blocker”, R. Henning (Hoechst, Frankfurt): “Benzthiazinones, Quinolones and Indolones as Calcium Channel Antagonists”, K. Schönafinger (Cassella AG, Frankfurt): “CAS-633: Synthesis and Ca^{2+} antagonistic properties of a chiral dihydropyridine”, J. Hebebrand (Univ. Bonn): “The Concept of Isoreceptors: Implications for the GABA / BZR”, U. Widmer (Roche, Basel): “Quinolizinone: new Benzodiazepine Receptor Ligands”, C. G. Wermuth (Univ. Strasbourg): “A unique Pharmacophore Model for Benzodiazepine Receptor Ligands”, H. I. Yamamura (Univ. Tucson): “Identification and Characterization of Neruotransmitter and Drug Receptors and their Subtypes”, R. K. A. Giger (Sandoz, Basel): “Serotonin Receptors”, M. P. Seiler (Sandoz, Basel): “Dopamine Receptors: Attempt of a Characterization using Agonists”, E. Mutschler (Univ. Frankfurt): “Differentiation of Muscarinic Receptors”, H. Schmidhammer (Univ. Innsbruck): “(-)-N-Cyclopropylmethyl-4,14-dimethoxymorphinan-6-one: a selective μ-opiate receptor antagonist”, E. Schmitz (Univ. Bonn): “Characterization of the cerebellar GABA / Benzodiazepine Receptor in different Species”, R. Schwyzer (ETH, Zurich): “Membrane-catalyzed Molecular Mechanism of Opioid and Neurokinin Receptor Subtype Selection”, R. Amstutz (Sandoz, Basel): “The position 5 in the Oxotremorin Sceleton”, W. Engel (Dr. Karl Thomae, Biberach): “Stereochemical Aspects of tricyclic Antimuscarinics”, V. Figala (Byk Gulden Lomberg, Konstanz): “Telenzepin: a new selective M1-Antimuscarinic Agent”, A. Storni (Ciba-Geigy, Basel): “Levoprotiline, a new Antidepressant Agent”, V. Rasetti (Ciba-Geigy, Basel): “Renininhibitors with a natural amino acid”, A. Cesura (Roche, Basel): “Ro 19-

6327: a new potent highly selective and reversible MAO-B Inhibitor", D. Gabel (Brookhaven National Laboratory, NY), "Boronated Thioureas as Compounds for the Neutron Capture Therapy of Melanomas", M. Halbach (Univ. Düsseldorf): "Cytotoxic Antibodies", B. Koppenhoefer (Univ. Tübingen), "Enantiomeric Purity of Endogenous Metabolites", R. Angerbauer (Bayer, Wuppertal): "Synthesis and SAR of Ammonium Cephalosporine Derivatives", J. Senn-Bilfinger (Byk Gulden Lomberg, Konstanz): "Mechanism of the selective Inhibition of gastric H^+, K^+-ATPase (Protonpump) by 2-(2-Pyridylmethylsulfinyl)-benzimidazole".

September 13-17, 1992, Basel, XIIth EFMC International Symposium on Medicinal Chemistry. Proceedings: "Perspectives in Medicinal Chemistry", VC/HCA, 1993. 42 lectures, 53 oral communications, 322 posters. 1200 participants. With the following topics:

Part A. David J. Triggle (Univ. Buffalo, NY): "The Future of Medicinal Chemistry".
Part B. Drugs Acting as Enzyme Inhibitors with lectures by D. H. Rich (Univ. Wisconsin, USA), D. Banner (Roche, Basel), K. James (Pfizer, Sandwich, UK) , R. Storer (Glaxo, Greenford, UK), R. B. Silverman (Northwestern Univ., Evanston, USA), M. Lang (Ciba-Geigy, Basel), J. Hartenstein (Goedecke, Freiburg), D. W. Brooks (Abbott, Illinois, USA), C. L. M. J. Verlinde (Univ. Washington, Seattle, USA),
Part C. Drugs Acting on Receptors with lectures by J.-C. Schwartz (INSERM, Paris), M. Wakimasu (Takeda, Tsukuba), R. M. Freidinger (Merck, West Point, USA), D. J. Carini (DuPont Merck, Wilmington, USA), W. Schilling (Ciba-Geigy, Basel), M. P. Seiler (Sandoz, Basel), P. D. Leeson (Merck, Harlow, UK), W. Froestl (Ciba-Geigy, Basel),
Part D. Drugs acting on Nucleic Acids and Nucleic acid processing Enzymes with lectures by H. E. Moser (Ciba-Geigy, Basel), L. H. Hurley (Univ. Texas, Austin, USA), K. R. Fox (Univ. Southampton, UK), H. Kohn (Univ. Houston, USA),
Part E. Drugs acting on Ion Channels with lectures by D. J. Nelson (Univ. Chicago, USA), J. Ramachandran (Neurex Corp., Menlo Park, USA), D. A. Claremon (Merck, West Point, USA),
Part F. Other Therapeutic Approaches with lectures by J. Adams (Boehringer Ingelheim, Ridgefield, USA), A. Stütz (Sandoz, Vienna), W. A. Taylor (Bayer, Stoke Poges, UK), C. W. Jefford (Univ. Geneva), F. C. A. Gaeta (Cytel Corp., San Diego, USA), T. A. Springer (Center for Blood Res., Boston, USA), T. Osawa (Yakult Central Institute for Microbiology Research, Tokyo),
Part G. Drug Design and Targeting with lectures by K. Hostettmann (Univ. Lausanne), C. P. Holmes (Affymax, Palo Alto, USA), M. M. Hayward (Yale Univ., New Haven, USA), K. Müller (Roche, Basel), S. S. Davis (Univ. Nottingham, UK), M. Hashida (Kyoto Univ.), S. Muranishi (Kyoto Pharmaceutical Univ.),
Part H. Molecular Toxicology with lectures by N. P. E. Vermeulen (Vrije Univ., Amsterdam), J. Caldwell (Imperial College, London, UK) and J. P. Uetrecht (Univ. Toronto, Canada).

September 26-28, 1993, Dijon, First Joint French-Swiss Meeting on Medicinal Chemistry. 16 lectures and 60 posters. 210 participants. With topics

Cardiovascular & Renal with contributions by:

Wolfram Bode (May Planck Institut für Biochemie, Martinsried) on the X-ray structure of α-thrombin, Soth Samreth (Fournier, Dijon) on orally active venous antithrombotics,

Ellen Van Obberghen-Schilling (INSERM, Nice) on the cloning of the α-thrombin receptor, Jean Bralet (Univ. Dijon) on mixed ACE and NEP inhibitors,

Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthritis: Immunosuppressive Agents with contributions by:

Sylvain Cottens (Sandoz, Basel) on the role of immunophilin binding of Cyclosporin A, FK-506 and rapamycin derivatives, Malcolm Walkinshaw (Sandoz, Basel) on X-rays of Cyclophilin-Cyclosporin A complexes, Roland Wenger (Sandoz, Basel) on the determination of the 3D structure of a cyclosporine A derivative in DMSO or water by NMR techniques, and Jean Martinez (Univ. Montpellier) on the mechanisms of action of gastrin

Oncologic, Endocrine & Metabolic with contributions by:

Peter Traxler (Ciba-Geigy, Basel) on inhibitors of EGF-R protein tyrosine kinases as potential anti-cancer agents, Rainer Albert (Sandoz, Basel) on tumour imaging of somatostatin receptor- positive tumours, Francis Loor (Univ. Strasbourg) on approaches to overcome Multi-Drug Resistance of cancer cells, Alain Pierre (Servier, Suresnes) on the MDR blocker S9788, Werner Leupin (Roche, Basel) on studies of interactions of DNA and DNA binding ligands by NMR-techniques,

Central & Peripheral Nervous System with contributions by:

Pascal George (Synthélabo, Bagneux) on the polyamine site antagonist Eliprodil, Walter Schilling (Ciba-Geigy, Basel) on non-peptidic antagonists of Substance P, Jean Pierre Maffrand (Sanofi, Toulouse) on non-peptidic antagonists of neurotensin,

September 23-26, 1997, Torino, First Italian-Swiss Meeting on Medicinal Chemistry. 23 lectures and 195 posters. 330 participants. Four Mini-Symposia on:

“Drugs acting on Enzymes” with contributions by: Joseph A. Martin (Roche, Welwyn, UK) on the discovery of the HIV protease inhibitor saquinavir, Jüergen Maibaum (Novartis, Basel) on the design of orally bioavailable peptidomimetic renin inhibitors, Markus Boehringer (Roche, Basel) on the discovery of β-lactamase-stable antibiotics, Violetta Cecchetti (Univ. Perugia) on the SAR of quinolone antibiotics, Gloria Cristalli (Univ. Modena) on SAR of adenosine deaminase inhibitors, Mario Varasi (Pharmacia & Upjohn, Milano) on novel kynurenate-3-hydroxylase inhibitors, Stephan Röver (Roche, Basel) on high affinity kynurenine 3-hydroxylase inhibitors, Vittorio Dal Piaz (Univ. Florence) on selective phosphodiesterase IV inhibitors, Paul J. Cox (Rhône Poulenc Rorer, Dagenham, UK) on a different class of selective phosphodiesterase IV inhibitors, and Cosimo Altomare (Univ. bari) on reversible MAO-B inhibitors.

“Drugs acting via Receptors” with contributions by: Susanna Cotecchia (Univ. Lausanne) on the mechanisms of activation of G-protein coupled receptors, Carlo Melchiorre (Univ. Bologna) on the concept of neutral and negative receptor antagonists, Pier Andrea Borea (Univ. Ferrara) on receptor-binding thermodynamics as a tool for linking drug efficacy and affinity, Didier Rognan (ETH Zurich) on structure based design of ligands for class-1 MHC proteins, Hans-Juergen Pfannkuche (Novartis, Basel) on 5-HT4 receptors, their agonists and antagonists, Daniele Donati (Glaxo, Verona) on glycine receptor antagonists, Luca F. Raveglia (SK&B, Milano) on NK-3 receptor

antagonists, and Stefano Ceccarelli (Biomedica Foscama, Ferentino) on non-xanthine adenosine A1 receptor antagonists.

“Drugs interfering with the Signal Transduction Pathway” with contributions by Paul Burn (Roche, Nutley, USA) on novel obesity targets, Jürgen Zimmermann (Novartis, Basel) on selective protein kinase inhibitors and Carlos Garcia-Echeverria (Novartis, Basel) on potent inhihitors of the Src homology 2 domain.

“Special Plenary Lectures” with contributions by Bernard Testa (Univ. Lausanne) on the manifold ramifications of xenobiotic metabolism and Roberto Pellicciari (Univ. Perugia) on new avenues for the search of neuroprotective agents.

March 22-23, 1999, Basel, Second Swiss/German Meeting on Medicinal Chemistry (see above, Spring Meeting of the SCS). 12 lectures. 80 participants.

July 1-4, 2003, Beaune, Second Joint French-Swiss Meeting on Medicinal Chemistry. 17 lectures and 86 posters. 290 participants. Four Mini-Symposia on:

“Ligands for selected G-protein coupled receptors” with contributions by Catherine Llorens-Cortes (Collège de France, Paris): “Orphan GPCR’s: from the ligand discovery to the physiological role. Application to Apelin”, Marcel Hibert (Univ. Strasbourg): “Post-genomic GPCR medicinal chemistry”, Claude Barberis (INSERM, Montpellier): “Structural and functional analysis of the vasopressin / oxytocin receptors” and Guy Griebel (Sanofi-Synthélabo, Bagneux): “Anxiolytic and antidepressant-like effects of non-peptide vasopressin V1b receptor antagonists”;

“Highlights in Medicinal Chemistry” with contributions by Christine Wurth (Roche, Basel): “Probing the sequence determinants of aggregation in the Alzheimer’s A-β peptide: non-amyloidogenic variants from libraries of random mutations”, Peter Toogood (Pfizer, Ann Arbor, USA): “Inhibition of protein-protein association as a target for drug discovery”, Paolo Carloni (SISSA, Trieste): “Role and Perspective of *ab initio* molecular dynamics in medicinal chemistry”, Didier Rognan (Univ. Strasbourg): “Synergistic use of chemical databases and target libraries in the context of high-throughput virtual screening” and Sabine Kolczewski (Roche, Basel): “Design and synthesis of potent and selective, orally active NK1 receptor antagonists”;

“Protein Kinase Inhibitors” with contributions by Martin Watterson (Northwestern University, Chicago, USA): “Protein Kinases as drug discovery targets”, David Grierson (CNRS-Institut Curie, Orsay): “Kinase-directed heterocycle libraries”, Laurent Meijer (Cell Cycle Laboratory, Roscoff): “Cyclin-dependent kinase inhibitors: mechanism of action, selectivity and potential applications” and Peter Traxler (Novartis, Basel): “Rational design of tyrosine kinase inhibitors – A challenge for medicinal chemists” and

“Progress in Oncology Research” with contributions by Herbert Waldmann ((Max Planck Institute für Molekulare Physiologie, Dortmund): “The ras-protein as a drug target”, Jeannette Wood (Novartis, Basel): “Angiogenesis as a therapeutic target: experience with VEGF receptor tyrosine kinase inhibitors”, Karl-Heinz Altmann (ETH Zurich): ”The chemistry and biology of epothilones” and Alex N. Eberle (University Hospital, Basel): “Peptides for tumour targeting”.

September 12-16, 2005. Second Joint Italian - Swiss Meeting on Medicinal Chemistry. 23 lectures, 19 short communications and posters. 260 participants. Six Mini-Symposia on the topics:

"Carbohydrate Chemistry in Drug Design" with contributions by Peter Seeberger (ETH, Zurich): "Automated Synthesis of Oligosaccharides as Basis for Drug Discovery: From Carbohydrate Array to Malaria Vaccine", Beat Ernst (Univ. Basel): "Carbohydrate Leads to Drugs: why is it so difficult?", Alessandro Dondoni (Univ. Ferrara): "Multicomponent Synthetic Approach to Reengineered Heterocycle Pharmacophores by Glycoside Decoration", Maria Pappalardo (Univ. Catania) "Glycopeptide- and Carbohydrate-based synthetic Vaccines for Cancer Immunotherapy";

Nuclear Receptors with contributions by: Roberto Pellicciari (Univ. Perugia): "The Farnesoid X Receptor and Drug Discovery. From Functions Unravelling to Therapeutic Exploitation", Marco Macchia "Salycilaldoximes and Anthranylaldoximes as Alternatives to Phenol-based Estrogen Receptor Ligands";

Progress in Design and Development of Protease Inhibitors with contributions by: Sylvain Cottens (Novartis, Basel): From Proteases to Protease Inhibitors to Drugs", Edwin Villhauer (Novartis, East Hannover, USA): "The story of Vildagliptin (LAF237): a DPP4 Inhibitor for the Treatment of Type 2 Diabetes", Katrin Groebke Zbinden (Roche, basel): "Towards Efficacious and Orally Bioavailable Tissue Factor / Factor VIIA InhibitorsMartin Missbach (Novartis, Basel): Selective and Orally Active Inhibitors of Cathepsin K – A Novel Treatment of Osteoporosis?", Vincenzo Summa (IRBM, Pomezia): "Progress in Hepatitis C Virus NS3 / 4a Serine Protease Inhibitors";

"Progress in Oncology Research" with contributions by: Dale Boger (Scripps Research Institute, La Jolla, USA): "Oncology Drug Discovery", Pier Giovanni Baraldi (Univ. Ferrara): "Titel", Ippolito Antonini (Univ. Camerino): "Bis Intercalator Derivatives as potential Antitumor Drugs", Maurizio Botta (Univ. Siena): A Pharmacophore Modeling Approach to Design new Taxol Mimics: Towards the Synthesis of potential Anticancer and MDR Reversing Agents", Karl-Heinz Altmann (ETH Zurich): "Recent Developments in the Chemistry and Biology of Epothilones";

"Pain": with contributions by: Romano di Fabio (GSK, Verona): "Glutamate and Pain: Identification of Novel Analgesic Agents", Terry Hart (Novartis, London): "New Approaches to the Treatment of Neuropathic Pain" and

"Neurodegenerative Diseases" with contributions by: Carlo Melchiorre (Univ. Bologna): "Multi-functional Drugs and Alzheimer's Disease", Alexander Alanine (Roche, Basel): "Identification of Potent Non-Competitive Group II Metabotropic Glutamate Antagonists", Roger Norcross (Roche, Basel): "Development of 2-Amino-Pyrimidines as selective Adenosine hA2a Receptor Antagonists", Novella Romanelli (Univ. Florence): "Design, Synthesis and Binding Affinity of New Nicotinic Ligands", Vincenza Andrisano (Univ. Bologna): "Alzheimer's Disease: in vitro Affinity Studies of potential Drugs to Biopolymeric Target by Fluorimetric, Circular Dichroism and HPLC Methods".

March 18-21, 2007. ‚Frontiers in Medicinal Chemistry' - Joint German-Swiss Meeting on Medicinal Chemistry (Berlin, Germany).
This meeting in Berlin has jointly been organized by the Medicinal Chemistry Division of Gesellschaft Deutscher Chemiker (GDCh), chaired by Dr. Hans Ulrich Stilz, the Division

Pharmazeutische/Medizinische-Chemie of the Deutsche Pharmazeutische Gesellschaft (DPhG), chaired by Prof. Bernd Clement, and the Division for Medicinal Chemistry of the Swiss Chemical Society, chaired by Hans Peter Märki.
Actually, this congress was the third Joint German-Swiss Meeting on Medicinal Chemistry, following the first one in Freiburg im Breisgau in 1987 and a follow-up in Basel in March 1999. It focused on recent developments and trends in the fields of Antiinfectives / Tropical Diseases, CNS Disorders / Neurodegeneration, Oncology, Technologies / Metabolism and other Highlights in Medicinal Chemistry. The concept of a well-balanced mixture of case studies and more educative lectures proved very attractive.
About 300 participants gathered in the capital of Germany, among them 33 from Switzerland. The nasty weather prevented them from exploring the tourist sights, and the lecture hall was almost always well patronized.

In detail, the lectures were given after the opening ceremony and in 5 mini-symposia:

Opening lecture: New compounds from nature, Clardy, J., Boston/USA.

Antiinfectives / Tropical Diseases:
Structure-based Design Approaches in the Development of New Leads Against Infectious Diseases, Diederich, F., Zurich/CH. Chemical Postevolution of Antibacterial Natural Products, Häbich, D., Wuppertal/D. Structural Biology in the Search of New Therapeutics for Tropical Diseases, Hol, W., Washington/D. Synthetic Peroxides and Novel Diamidines for Malaria and African Sleeping Sickness Brun, R., Basel/CH. Development of Benzophenone-Derivatives as Anti-Protozoic Agents Schlitzer, M., Marburg/D. New Approaches in the Fight Against Tropical Diseases, Matter, A., Singapore/SGP.

CNS Disorders / Neurodegeneration:
Pathologies of Alzheimer's Disease and Perspectives for Causal Therapies, Jacobsen, H., Basel/CH. Gamma-Secretase Inhibitors, Audia, J. E., Indianapolis/USA. Design, Synthesis and Characterization of Selective Dopamine D3 Receptor Antagonists for the Treatment of Schizophrenia, Haupt, A., Ludwigshafen/D.

Oncology
Biotherapeutics for Treatment of Cancer, Trikha, M., San Francisco/USA. Natural Products as Lead Structures in Oncology Research, Kalesse, M., Hannover/D. Discovery of and structural biology studies with nilotinib, a selective BCR-ABL inhibitor for CML, Manley, P. W., Basel/CH. Selective inhibitors of the mitotic kinesin-5, Schiemann, K., Darmstadt/D.

Technologies / Metabolism
Detection of Reactive Metabolite Formation in Early Drug Discovery. Baillie, T. A., West Point/USA. Development of Novel Functional Fluorescence Probes Based on Rational and Flexible Design Strategies. Urano, Y., Tokyo/J. Milestones and Challenges in the Prediction of Human Metabolism, Cruciani, G., Perugia/I. Minimising the Potential for Metabolic Activation in Drug Discovery, Kalgutkar, A. S., Groton/USA. Role of Pharmacologically Active Metabolites in Drug Discovery and Development, Fura, A., Princeton/USA.

Highlights in Medicinal Chemistry

The Synthetic Development of the Anti-Influenza Neuraminidase Inhibitor Oseltamivir Phosphate (Tamiflu®): A Challenge for Synthesis & Process Research, Karpf, M., Basel/CH. Synthetic Heparin: From Fondaparinux and Idraparinux to a Novel Carbocarrier Technology for Therapeutic Proteins, van Boeckel, S., Oss/NL. Small molecule CCR2 antagonists for the treatment of inflammatory and autoimmune Diseases, Yang, L., Rahway/USA. Studies in Asymmetric Synthesis, Carreira, E. M., Zurich/CH.

Meetings supported by DMC

June 8-11, 1993, Interlaken, **"**12th Annual Conference of the Molecular Graphics Society"
March 21-24, 1995, Lausanne, "Symposium on Lipophilicity in Drug Research and Toxicology"
July 23-27, 1995, Zürich, "The 9th International Conference on Cytochrome P-450"
September 1-6, 1996, Lausanne, "XIth European Symposium on Quantitative Structure-Activity Relationships"
August 17-22, 1997, Geneva, "36th IUPAC Congress".

Participation in the Autumn Meetings of SCS

October 21, 1988, Bern (together with the Section for Organic Chemistry): J.-L. Fauchère "Design and Synthesis of Peptide Mimetics" and R. H. Abeles "Inhibition of Serine Proteases and Esterases by Fluoroketones".
October 20, 1989, Bern, C. R. Ganellin "Designing Drugs for Histamine Receptors"), B. Testa: "Mechanism of Chiral Recognition in Pharmacokinetic and Pharmacodynamic Processes" and 12 short communications.
October 19, 1990, Bern, 13 short communications.
October 18, 1991, Bern: 6 short communications.
1992: no participation due to "XIIth International Symposium on Medicinal Chemistry", Basel.
October 22, 1993, no participation due to "First Joint French-Swiss Meeting on Medicinal Chemistry", Dijon.
October 21, 1994, Bern, 6 short communications.
October 20, 1995, Bern, 9 short communications and posters.
November 21, 1996, Basel, 8 short communications and posters.
October 15, 1997, Lausanne, 10 short communications and posters.
October 15, 1998, Zurich, 14 short communications and posters.
October 12, 1999, Basel, 8 short communications and posters.
October 12, 2000, Lausanne: 10 short communications and 4 posters
October 12, 2001, Zurich: 12 short communications and 1 poster
October 17, 2002, Basel: 14 short communications and 8 posters.
October 9, 2003, Lausanne: 22 short communications, 4 posters with oral presentation, 5 posters.
October 7, 2004, Zurich: 16 short communications and 11 posters
October 13, 2005, Lausanne: 17 short communications and 16 posters [Mettler Toledo Prices were given to Helene Fiaux (EPFL Lausanne) und Mark Rogers-Evans (Roche) (oral presentations) and Oliver Schwardt (poster)].
October 13, 2006, Zürich: 17 short communications and 18 posters [Mettler Toledo Prices were given to Fabian Feyen (ETH) and Alexander Lederer (Polyphor) (oral presentations) and Alexander Titz (poster)].

September 12, 2007, Lausanne, 17 short communications (19 planned, 2 cancelled) and 27 posters [Mettler Toledo Prices were given to Anna Hirsch (ETH) (oral presentation) and Samuel Luisier (poster)].
September 11, 2008, Zürich, 14 short communications and 32 posters [Mettler Toledo Prices were given to Jean-Marc Plancher (Roche) (oral presentation) and Gabriele Meloni (poster)].

Participation in the Scientific Program of ILMAC (r + d in life sciences)

October 14, 1999, Basel: 2 Mini-Symposia:
"Molecular Modeling for Drug Design" with contributions by A. Caflisch "Structure-Based Combinatiorial Ligand Design: Methods and Applications", M. D. Varney "Highlights of the last 10 Years of Structure-Based Drug Design at Agouron" and P. Willett "Applications of Cheminformatics in Drug Discovery".
"HTP-Purification, Analysis and Quantification of Combinatorial Libraries" with contributions by D. Reynolds "Combined Use of HPLC, MS and NMR for High Throughput Analysis, Purification, and Quantification", H. N. Weller "Application of Preparative HPLC to Purification of Automated Synthesis Products in Drug Discovery" and D. B. Kassel "From High Throuput Parallel Synthesis to High Throughput Parallel Analysis and Purification: Existing and Emerging Tools to Adress the Analytical Bottleneck in Combinatorial Chemistry".

October 16, 2002, Basel: 2 Mini-Symposia:
“Ligand-receptor interactions: from understanding to design” (G. Folkers, chairman) with contributions by H. Kubinyi “Understanding ligand-receptor interactions”, R. Hoffmann “Chemical feature based pharmacophores as useful tools for lead identification”, L. Scapozza “Design of genetic switches” and W. Jahnke “NMR in drug discovery”.
“Structure – properties - relationships and kinetics” (M. Kansy, chairman) with contributions by P.-A. Carrupt “Molecular fields and permeation”, A. Avdeef “Physico-chemical profiling”, G. Klebe “Computational approaches to functional similarity among proteins” and L. Balant “Pharmacokinetics”.

May 25, 2005, Basel.
Scientific Morning Session:
The Fate of Drugs in the Body - Mechanisms Involved in Uptake, Distribution and Elimination of Pharmaceuticals: with contributions by Jean-Michel Scherrmann (Hôpital Fernand Widal, Paris) “Expression and functional role of multidrug resistance transporters at the blood-brain barrier”, Joerg Huwyler (F. Hoffmann-La Roche, Basel) “Relevance of P-glycoprotein for the development of CNS compounds”, Alex Avdeef (pION Inc., Boston) “Prediction of Rodent *in situ* Brain Uptake using an *in combo* Model, based on Double-Sink PAMPA (Parallel Artificial Membrane Permeability Assay)” and Bernard Faller (Novartis, Basel) “Combination of in-silico and experimental approaches in lead discovery profiling”.
Special Evening Session:
Jean-Paul Clozel (CEO of Actelion Pharmaceuticals Ltd., Allschwil): “Actelion: A New Global Player in the Biotech Industry?”

Executive Committees of the DMC 1990-2010

In September 1990 the members of DMC elected the Executive Committee for the period 1991-1992, 178 of the 314 members voting via mail. E. Kyburz (chairman), R. Giger (vice-chairman), A. Storni (treasurer), W.-D. Woggon (secretary), W. Froestl, D. Hauser, J. Kalvoda, B. Testa and P. Wyss were elected.

Executive Committee elected in 1992 for the period 1993-95: E. Kyburz (chairman), R. Giger (vice-chairman), A. Storni (treasurer), P. Wyss (secretary), W. Froestl, D. Hauser, J. Kalvoda, B. Testa and W.-D. Woggon.

Executive Committee elected in 1995 for the period 1996-1998: R. Giger (chairman), E. Kyburz (vice-chairman), W. Froestl (treasurer), P. Wyss (secretary), P. Acklin, K. Burri, G. Folkers, H. van de Waterbeemd, W.-D. Woggon and R. Ziegler.

Executive Committee (elected for the period 1999-2001)**:** Rudolf Giger (chairman), Wolfgang Froestl (vice-chairman), Hans Peter Märki (treasurer), Peter Mohr (secretary), Geo Adam, Karl-Heinz Altmann, Quirico Branca, Alex Eberle, Beat Ernst, Gerd Folkers and Emilio Kyburz.

Executive Committee (elected for the period 2002-2004)**:** Wolfgang Froestl (chairman), Hans Peter Märki (vice-chairman and treasurer), Rudolf Giger (past-chairman), Peter Mohr (secretary), Karl-Heinz Altmann, Sylvain Cottens, Alex Eberle, Beat Ernst, Philipp Floersheim (webmaster), Gerd Folkers, M. Kansy.

Executive Committee (elected for the period 2005-2007)**:** Hans Peter Märki (chairman), Wolfgang Froestl (past-chairman), Sylvain Cottens (vice-chairman and treasurer), Peter Mohr (secretary), Karl-Heinz Altmann, Alex Eberle, Beat Ernst, Philipp Floersheim (webmaster), Gerd Folkers, Manfred Kansy, Werner Neidhart.

Executive Committee (elected for the period 2008-2010)**:** Hans Peter Märki (chairman), Yves Auberson (vice-chairman and treasurer), Peter Mohr (secretary, delegate to EFMC), Karl-Heinz Altmann, Alex Eberle, Beat Ernst (Leysin MedChem Course - Main Organizer), Nikolaus Stiefl (webmaster), Gerd Folkers (Leysin MedChem Course – Co-Organizer), Manfred Kansy, Werner Neidhart, Leonardo Scapozza.

Information on the DMC published in Chimia

Chimia 46 (1992), 7/8, 295-344: XIIth International Symposium on Medicinal Chemistry, Basel, September 13-17, 1992.

Chimia 47 (1993), 11, 438-439: First Joint French-Swiss Meeting on Medicinal Chemistry, Dijon.

Chimia 48 (1994),7/8, 322: Report on 5th Annual Meeting.

Chimia 48 (1994) 12, 576-577: First Swiss Course on Medicinal Chemistry, Leysin, October 9-14, 1994.

Chimia 49 (1995), 10, 359-395: Editorial "The Interdisciplinary Task of Medicinal Chemists" and Articles on various aspects of medicinal chemistry.

Chimia 50 (1996), 1/2, 37: Annual Report 1995

Chimia 50 (1996), 6, 257-270: Mini-Symposium 1996: Synthesis of small molecules on solid phase.

Chimia 50 (1996), 7/8, 310-313: Abstracts of the presentations on the Fall Meeting 1996

Chimia 51 (1997), 8/9, 594-598: Abstracts of the presentations on the Fall Meeting 1997

Chimia 51 (1997), 11, 819-845: Special edition: Medicinal Chemistry.

Chimia 52 (1998), 1, 80: Annual Report 1997.

Chimia 51 (1998), 9, 446-450: Abstracts of the presentations on the Fall Meeting 1998.

Chimia 52 (1998), 9, 503-505: Mini-Symposium 1998: Bioavailability in Drug Discovery and Development.

Chimia 52 (1998), 12, 743-744: Third Swiss Course on Medicinal Chemistry, Leysin, October 11-16, 1998.
Chimia 53 (1999), 1, 47: Annual Report 1998.
Chimia 53 (1999), 6, 295-304: Second Swiss/German Meeting on Medicinal Chemistry, March 22-23, 1999 in Basel.
Chimia 53 (1999), 7/8, 331-333: Abstracts of the presentations on the Fall Meeting 1999
Chimia 54 (2000), 1, 71: Annual Report 1999.
Chimia 54 (2000), 7/8, 406-410: Abstracts of the presentations on the Fall Meeting 2000
Chimia 54 (2000), 7/8, 478-481: Mini-Symposium 2000: Chemical Mechanisms of Toxicity. Basic Knowledge for Designing Safer Chemicals.
Chimia 55 (2001), 1, 85: Annual Report 2000.
Chimia 55 (2001), 7/8, 673-675: Mini-Symposium 2001: Case Histories of Drug Design
Chimia 55 (2001), 7/8, 597-600: Abstracts of the presentations on the Fall Meeting 2001
Chimia 56 (2002), 1, 37: Annual Report 2001.
Chimia 56 (2002), 5, 243: Sandmeyer Prize of the Swiss Chemical Society awarded to Dr. Jürg Zimmermann.
Chimia 56 (2002), 7/8, 339-345: Abstracts of the presentations on the Fall Meeting 2002
Chimia 56 (2002), 7/8, 428-431: J. Zimmermann: Glivec: a new treatment modality for CLM: a case history.
Chimia 56 (2002), 11, 657-658: Nauta Award conferred to Prof. B. Testa, UCB Award to Dr. J. Zimmermann.
Chimia 57 (2003), 1, 83: Annual Report 2002.
Chimia 57 (2003), 7/8, 395-402: Abstracts of the presentations at the Fall Meeting 2003.
Chimia 58 (2004), 1, 54-61: Conference Report: Second Joint French-Swiss Meeting on Medicinal Chemistry. 39èmes Rencontres Internationales de Chimie Thérapeutique, Beaune, July 1-4, 2003.
Chimia 58 (2004), 1, 71: Annual Report 2003.
Chimia 58 (2004), 3, 166-167: Invitation to Mini-Symposium “Research Concepts of Swiss Startup Companies” on May 13, 2004 in Basel.
Chimia 58 (2004), 7/8, 461-468: Abstracts of the presentations at the Fall Meeting 2004.
Chimia 58 (2004), 10, 745-752: Conference Report: research Concepts of Swiss Startup Companies
Chimia 58 (2004), 11, 812: First advertisement of ILMAC 2005.
Chimia 58 (2004), 12, 911: 2nd advertisement of ILMAC 2005.
Chimia 59 (2005), 1, 47-48: Annual Report 2004.
Chimia 59 (2005), 1-2, 52: 3rd advertisement of ILMAC 2005.
Chimia 59 (2005), 3, 129-132: 4th advertisement of ILMAC 2005.
Chimia 59 (2005), 4, ILMAC issue, especially page 169-170: 5th advertisement of ILMAC 2005.
Chimia 59 (2005), 4, 180-181: Advertisement for the 2nd JOINT ITALIAN – SWISS MEETING ON MEDICINAL CHEMISTRY; Modena, ITALY,September 12-16, 2005.
Chimia 59 (2005), 11, 851-861: Conference Report: 2nd JOINT ITALIAN – SWISS MEETING ON MEDICINAL CHEMISTRY; Modena, ITALY,September 12-16, 2005.
Chimia 60 (2006), 3, 154-155: Advertisement for the Mini-Symposium: Imaging in Biomedical Research.
Chimia 60 (2006), 11, 805-814: Conference Report: Imaging in Biomedical Research: Mini-Symposium of the Division for Medicinal Chemistry (DMC) of the Swiss Chemical Society (SCS), at the Department of Chemistry, University of Basel, May 18, 2006.
Chimia 60 (2006), 12, 859: Advertisement for Joint German-Swiss Meeting on Medicinal Chemistry - March 18-21, 2007 – Berlin.

Chimia 61 (2007), 9, 580-586: Conference Report: Frontiers in Medicinal Chemistry - Joint German-Swiss Meeting on Medicinal Chemistry; Berlin, Germany, March 18-21, 2007.
Chimia 62 (2008), 3, 176-177: Advertisement for the Mini-Symposium: Drug Targeting.
Chimia 62 (2008), 3, 180: Advertisement for the 8th Swiss Course on Medicinal Chemistry.

Prize Winners among DMC Members

2002 Nauta Award on Pharmacochemistry: Prof. Bernard J. Testa
2002 Sandmeyer Prize of the Swiss Chemical Society: Dr. Jürg Zimmermann
2002 UCB Award for Excellence in Medicinal Chemistry: Dr. Jürg Zimmermann
2008 UCB - Ehrlich Award for Excellence in Medicinal Chemistry, Prof. Peter Seeberger

Future Activities of the DMC

The DMC will continue its efforts to offer to the Swiss community of scientists dedicated to drug research high quality professional meetings and courses. It considers frequent exposure to international standards of research and the establishment of personal contacts during these events as essential for the advancement of own research projects. We therefore encourage our members to profit from the opportunities offered by the DMC for their own professional development, and to participate actively in our events. Suggestions and help are highly welcome and will contribute to improve our work! Finally we like to thank all those who have supported directly or indirectly our endeavours with advice, work and financial means.

March, 15–18, 2009, Frontiers in Medicinal Chemistry - Joint German-Swiss Meeting on Medicinal Chemistry; Heidelberg, Germany (www.gdch.de/medchem2009).

Friday, September 04, 2009, Fall Meeting SCS, EPFL Lausanne, (organized by Prof. Sandrine Gerber).

Homepage of the DMC

The Homepage of the DMC was established in spring 1996. It can be accessed directly (http://www.scg.ch/smc/home.htm or http://www.swiss-chem-soc.ch/smc/home.htm) or via Homepage of the SCS (http://www.scg.ch or http://www.swisschemistry.ch). Links to the Homepage of the EFMC (http://www.efmc.info/), IUPAC and other Medicinal Chemistry Homepages have been implemented

How to become a member of the DMC-SCS

You wish to become a member of the DMC-SCS? Click "Become a member" on the Homepage of the SCS. You may print out the "Registration form" or click on "interactive www" and register via the internet using "Application for Membership".
For all inquiries, suggestions and comments please do not hesitate to contact the members of the Executive Committee, their addresses are on the Homepage or contact the SCS-Secretariat: Swiss Chemical Society (SCS), Dr. Lukas Weber, Secretary General, Schwarztorstr. 9, CH-3007 Bern .Tel. +4131 310 40 90; Fax +4131 312 16 78; E-mail: info@scg.ch; Internet: http://www.scg.ch.